Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.45 |
| ▸ | ITK | Q08881 | 11/20 | 0.44 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | CCNH | P51946 | 2/20 | 0.39 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26076556 | 1.00 | EGFR (0.45) | EGFRITKBTKJAK3CCNA2 | |
| Formic Acid SCHEMBL30595871 | 0.98 | EGFR (0.43) | EGFRITKBTKJAK3CCNA2 | |
| SCHEMBL26074894 | 0.93 | EGFR (0.50) | EGFRITKBTKJAK3 | |
| SCHEMBL30590720 | 0.93 | EGFR (0.50) | EGFRITKBTKJAK3 | |
| Formic Acid SCHEMBL30595851 | 0.91 | EGFR (0.48) | EGFRITKBTKJAK3 | |
| SCHEMBL26075404 | 0.86 | MAPK8 (0.41) | JAK3CDK2 | |
| SCHEMBL30595902 | 0.86 | MAPK8 (0.41) | JAK3CDK2 | |
| Formic Acid SCHEMBL25423226 | 0.84 | MAPK8 (0.38) | EGFRBTKJAK3CDK2 | |
| Formic Acid SCHEMBL29537715 | 0.84 | MAPK8 (0.38) | EGFRBTKJAK3CDK2 | |
| SCHEMBL26077875 | 0.82 | MAPK14 (0.34) | EGFRBTKJAK3CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | EGFR 58/4885ITK 270/4885BTK 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.